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The Prevent Cancer Foundation Lung Cancer Workshop XI: 
Tobacco-Induced Disease: Advances in Policy, Early Detection and 
Management was held in New York, NY on May 16 and 17, 2014. The 
two goals of the Workshop were to define strategies to drive innovation 
in precompetitive quantitative research on the use of imaging to assess 
new therapies for management of early lung cancer and to discuss a 
process to implement a national program to provide high quality com-
puted tomography imaging for lung cancer and other tobacco-induced 
disease. With the central importance of computed tomography imaging 
for both early detection and volumetric lung cancer assessment, strate-
gic issues around the development of imaging and ensuring its quality 
are critical to ensure continued progress against this most lethal cancer.
Key Words: Lung cancer, Screening, Low Dose CT, Quantitative 
imaging, Volumetric CT.
(J Thorac Oncol. 2015;10: 762–767)
INTEGRATION OF QUANTITATIVE IMAGING 
INTO LUNG CANCER: KEYNOTE ADDRESS: 
BRINGING PRECISION QUANTITATIVE IMAGING 
TO MANAGE MAJOR CHRONIC DISEASES
In his overview remarks, Dr. Mulshine outlined that 
The Prevent Cancer Foundation has sponsored a lung cancer 
quantitative imaging workshop since 2004, in which the faculty 
jointly considers how to more rapidly advance the application of 
quantitative computed tomography (CT) imaging in the manage-
ment of early lung cancer.1 At the onset of this Workshop series, 
it seemed highly improbable that on December 31, 2013, the 
United States Preventive Services Task Force (USPSTF) would 
make a final recommendation for the use of spiral CT in the early 
detection of 55-year-old and older, ever smokers as an evidence-
based recommendation.2 From a screening implementation per-
spective, the other remarkable development was the provision in 
new federal legislation (the Affordable Care Act) requiring every 
commercial payer to implement a plan for the delivery cancer 
screening service recommended by the USPSTF, without any 
copay, as a routine service.3 Because of the confluence of these 
two events, at the 11th Prevent Cancer Foundation Workshop, 
Tobacco-induced Disease: Advances in Policy, Early Detection 
and Management, we are on the brink of national implementa-
tion of low-dose CT (LDCT) cancer screening.
The issues surrounding the national implementation of 
LDCT emerged as the central focus of workshop. The workshop 
steering committee’s technical experts included David Yankelevitz, 
an early proponent of applying quantitative imaging to lung cancer 
management; Thomas Baer, a pioneer in the biomedical applica-
tions of optics; Rick Avila, an early and highly productive con-
tributor to quantitative imaging and the open source imaging field; 
and Raul San Jose Estépar, an expert on quantitative techniques 
for CT assessment of chronic obstructive pulmonary disease 
(COPD) and other forms of lung injury. The steering commit-
tee also included two internationally prominent leaders in patient 
advocacy, Carolyn Aldigé of the Prevent Cancer Foundation and 
Laurie Fenton Ambrose of the Lung Cancer Alliance (LCA).
The goal set by the Committee was to convene a highly 
interactive forum of leaders to outline key technical priorities in 
improving the quantitative imaging process for managing early 
lung cancer, with the goal of reducing its mortality burden. A 
distinctive aspect of this forum is that a parallel goal was to for-
mulate a way forward for the early lung cancer detection process 
from a health policy perspective. The dialogue between experts in 
technical quantitative imaging issues and experts in health policy 
created a challenging but critical conversation because these two 
divergent fields rarely have occasion to otherwise interact.
In this forum, we also have been reviewing progress with 
the application of quantitative imaging to not only detect early 
lung cancer but also to evaluate early coronary artery disease 
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and COPD. LDCT is emerging as an informative biomarker of 
these other two frequent complications of tobacco exposure. 
The goal is to leverage the full thoracic imaging information 
acquired in the course of performing a LDCT screening not 
only about lung cancer but also about the status of the coro-
nary arteries and lung parenchymal injury. This more com-
prehensive information could enrich the dialogue with lung 
screen screening subjects regarding other possible sites of 
tobacco-related thoracic disease risk as these additional imag-
ing data are available without additional cost and enhance the 
efficiency of this large new screening investment.
QUANTITATIVE LUNG IMAGING AND THE 
RADIOLOGICAL SOCIETY OF NORTH AMERICA
The workshop has been successful in advancing the 
dialogue on how to best integrate quantitative imaging into 
early lung cancer in large part because of collaborations with 
other professional organizations that share an interest in the 
field of quantitative imaging including the Radiological 
Society of North America (RSNA).4 This year the keynote 
address, entitled “Bringing Precision Quantitative Imaging 
to Manage Major Chronic Diseases,” was given by Dr. Dan 
Sullivan who chairs the Quantitative Imaging Biomarker 
Alliance (QIBA) of RSNA. In his presentation, Dr. Sullivan 
emphasized two key factors: “consistency,” reflecting the 
need for standardization, and the challenge of “false posi-
tives,” indicating the need for objective interpretations. 
Neuroimaging as conducted by the Alzheimer’s Disease 
Neuroimaging Initiative was presented by Dr. Sullivan as 
an example of an inclusive collaborative publicprivate part-
nership between investigators and the Institute of Medicine 
to develop a forum to address relevant issues in an ongo-
ing process.5 He then pointed out that variance in clinical 
medicine leads to less favorable clinical outcomes, and 
that precise quantitative imaging is a potential solution to 
address this problem. To explore this opportunity in 2007, 
QIBA was formed to catalyze the process of “industrializ-
ing” imaging biomarkers.6 The criteria that QIBA employs 
for selecting imaging biomarkers to work on include whether 
the biomarker is transformational, which implies addressing 
a significant medical need, and its likelihood of resulting in 
significant improvement in the development, approval, or 
delivery of care to patients. Another major selection factor 
is whether the biomarker is feasible, and the end goals can 
likely be achieved in a specific time frame. A related factor 
is whether the biomarker is practical, meaning it leverages 
preexisting resources (e.g., workflows, personnel, facilities, 
specimens, reagents, and data) wherever possible, and there-
fore, warrants access to RSNA resources and support. A key 
strategy for this QIBA effort is to accelerate progress by rou-
tinely collaborating with other relevant partners with content 
expertise in the specific area of care.
METHODOLOGICAL ISSUES WITH 
QUANTITATIVE IMAGING
Spiral CT is one of the key modalities for quantita-
tive development with QIBA, because the CT signal is lin-
early proportional to density and has particularly favorable 
spatial resolution characteristics, so it can be quite accurate 
for distance measurements. The approach that QIBA has 
developed entails a four-stage process, including identifica-
tion of sources of error and variation, evaluating specific 
solutions to overcome the challenges, and then codifying 
those solutions in the form of a narrative process document 
that is called a “QIBA Profile.” The performance of the 
proscribed profile process is then formally tested, and the 
key components of the solution are promulgated as a “pro-
file” for vendors and users: first, minimize image acquisi-
tion variability, outline factors for the radiologist to reduce 
reader variability, and then finally minimize measurement 
methods variability.7
To make progress on the goals of QIBA, it has been nec-
essary to define new methodologies for rigorous assessment 
of lesion volume quantitation. A recent supplement contains a 
series of papers that discuss a number of complex but critical 
issues involved in these analyses. This supplement is entitled, 
“Developing Metrology Standards for QIBA: Terminology, 
Technical Performance, Algorithm Comparisons,” and this 
issue is in press in the journal Statistical Methods in Medical 
Research. The editors of this landmark issue are Drs. Nancy 
Obuchowski, Larry Kessler, and David Raunig. The output of 
all of this work is to more clearly define the validation pro-
cess. For example, in a profile document, the steps necessary to 
perform a quantitative image study are defined in a step-wise 
fashion. The expectation is that if the profile steps are carefully 
followed then a “claim” statement would relate t how reliably 
precise and consistent the volumetric image measurement is 
likely to be.8,9
A number of research projects have been funded by 
QIBA to sort out complex issues in regard to defining the 
expected amount of variance with imaging volume measure-
ment. At this stage, in the development of the field, this has 
involved working with phantoms and synthetic digital refer-
ence objects to enable an objective source of ground truth 
for accurate volume measurement. The goal of QIBA is to 
demonstrate actual improved clinical measurement precision 
through deployment of its protocols.
Much of the discussion during the workshop focused on 
the specific use case of moving LDCT screening forward now 
that the USPSTF has recommended this early cancer detec-
tion tool. Moving this service into the realm of routine clini-
cal care, so that it is readily available at high quality across 
the nation, is a foundational challenge for quantitative imag-
ing. Having the conditions established, so that measurement 
of pulmonary nodules can consistently be performed with 
acceptable variance across all different types of CT scanners, 
remains an open challenge, and there is much intense interest 
in this particular issue.
HOW QUANTITATIVE IMAGING CAN IMPACT 
SCREENING MANAGEMENT
Claudia Henschke of Mt. Sinai discussed an example of 
how lung cancer screening management improvement could 
evolve using “big data.” In a recently published analysis, 
Henschke used screening outcomes of 22,000 screening sub-
jects to explore the likelihood of being diagnosed with lung 
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cancer as a function of the size of the first pulmonary nodule 
detected by LDCT screening. The conclusion of the analysis 
is that the diagnostic work-up efficiency could be improved by 
moving from a smaller size threshold for diagnostic work-up 
(5 mm) to a larger threshold such as >6 mm.10 The validity of 
this approach was confirmed, using the released data from the 
National Lung Screening Trial (NLST), which demonstrated a 
similar improvement in reducing the frequency of nonproduc-
tive diagnostic work-up by using a 6-mm nodule size thresh-
old for diagnostic work-up rather than the 4-mm threshold 
used in the NLST.11
STATUS OF HARMS REDUCTION: DOSE 
MINIMIZATION
In the image processing approach, iterative reconstruc-
tion was presented as a software development to discriminate 
critical image signals from background noise to improve the 
process of lung cancer screening.12 A critical aspect of iterative 
reconstruction approaches is the potential to reduce the aver-
age medical radiation dose required for a quality LDCT by 
up to 80% compared with the exposures used in the NLST.13 
However, further research is required to fully understand how 
this tool can be best applied within the complex setting of 
lung cancer screening without confounding consistent image 
quantitation.
A focus of the workshop was a discussion on how to best 
capture the useful screening data for reanalysis, such as with 
developing a screening imaging registries to monitor quality 
assurance of this cancer detection service. It was recognized 
that a model for quality monitoring comes from the American 
College of Radiology where there is a program to monitor 
CT scan dose.14 The system involves deidentified data sent to 
a central repository where it is analyzed, and reports are sent 
back to individual sites that provide summary dose reports and 
comparisons to other facilities. It was also recognized that the 
opportunity will exist to go beyond reporting parameters that 
can be extracted from the digital imaging and communications 
in medicine (DICOM) files, which are the standard format for 
digital image storage for medical images. The opportunity 
exists for reanalyzing the original clinical image data directly 
using software that can characterize actual image quality or 
other relevant features. In this way, a more comprehensive 
quality assessment can be provided, or new image analysis 
tools can be validated using collections of serially acquired 
DICOM image files with known clinical outcomes. In light of 
such opportunities, it was also recognized that standard mea-
sures of CT image quality will continue to evolve, and there 
is a need to develop newer metrics beyond those traditionally 
measured, such as noise or resolution. Overall, the workshop 
concurred on the idea to develop a large, easy-to-use quality 
assurance registry including a large number of clinical images 
files with ongoing metadata. With appropriate regulatory com-
pliance, this reference image data set should be made available 
to catalyze image quantitation and related screening process 
research. This resource was considered to be vitally important 
to the success of screening, and that the International Early 
Lung Cancer Action Program research model represents a 
model for how such a registry can be developed.
WHAT IS THE PRECISION OF CURRENT LUNG 
CANCER SCREENING QUANTITATION?
A pressing technical issue related to quantitative imag-
ing relative to lung cancer screening is a precise measurement 
of small pulmonary nodules. Volumetric change percentage 
thresholds are critical when assessing if a solid lung lesion is 
changing size during assessment for malignant potential. Mr. 
Rick Avila presented an analysis of underlying mathematical 
models combined with verification using several lung cancer 
imaging datasets that was used to arrive at minimum volu-
metric change recommendations for different ranges of lesion 
diameters. Specifically, the following volumetric change 
percentages are likely to exceed known sources of change 
measurement variation between two consecutive volumetric 
measurements for solid lesions:
These preliminary findings were presented with the goal 
of making further refinements in preparation for utilization 
in the small-nodule QIBA profile and other lung cancer CT 
imaging guidance documents. One of the technical acquisi-
tion issues of concern for nearly all current CT scanners is 
the low-axial in-plane sampling rate (i.e., “matrix size”), cur-
rently supported with 512 × 512 pixels per image. Mr. Avila 
proposed that CT scanner manufacturers support an additional 
matrix size of 1024 × 1024 pixels per acquired CT image, 
which would allow for significant improvement in detection 
and measurement performance.
FUTURE ADVANCES: ASSESSING OTHER 
THORACIC STRUCTURES WHILE SCREENING
An important emerging question in this regard is whether 
the conditions to permit optimal lung screening imaging are 
also optimal to evaluate other organ systems that are included 
in the field of view on the lung cancer screening image. In 
the course of lung cancer screening, evaluation of coronary 
artery calcium (CAC), COPD, and breast cancer is possible. 
However, the image resolution for certain of these evaluations 
may not be sufficient.
An example of where concern for optimal imag-
ing acquisition parameters in lung cancer screening is with 
quantitative CT assessment for the presence or progression 
of early COPD in this heavily smoke-exposed population. 
A major resource for answers in this regard is the consortium 
funded by the National Heart Lung and Blood Institute con-
ducting the COPDGene Project.15 In his overview, Dr. Raul 
San Jose Estépar commented on imaging approaches used to 
quantify disruption in lung structure (parenchyma, airways, 
and vasculature) and outlined which of these measurements 
be assessed by the imaging technique routinely used LDCT.16 
He also pointed out how COPD outcomes mirror the severe 
Lesion Diameter (D)
Volumetric  
Decrease (%)
Volumetric  
Increase (%)
5 mm ≤ D < 8 mm −85 +110
8 mm ≤ D < 11mm −32 +35
11 mm ≤ D < 14 mm −21 +23
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morbidity and mortality experienced with lung cancer, so 
these are important analyses to perform jointly.17 Moreover, 
he demonstrated how quantitation of other structures, such as 
the pectoralis muscle, is a more informative biomarker than 
body mass index for outcomes with pulmonary diseases18; 
thus, quantitative CT can bridge the gap between structure 
and clinical function for tobacco-related lung disease. This 
research suggests that information from LDCT screening has 
significant potential to also inform about the risk of premature 
death related to COPD in addition to lung cancer.
In a provocative presentation, Dr. Harvey Hecht revealed 
that imaging CAC with a dedicated CT study correctly reclas-
sifies 25% of all patients and 67% of intermediate risk patients 
as determined by Framingham risk scores; therefore, CAC is 
considered a most informative clinical risk prognosticator. Dr. 
Hecht outlined that the target high-risk population for LDCT 
overlaps with the target population at-risk for atherosclerotic 
disease. Moreover, on the basis of early studies, coronary cal-
cium analysis done on LDCT, including gated and nongated 
measures, is highly correlated with results from dedicated 
standard dose CAC scoring. Hecht reviewed the important 
technical differences between the different approaches to 
image acquisition and scoring methods and suggested that the 
LDCT study can be adapted to perform an informative CAC 
study within the boundaries of currently acceptable image 
acquisition protocols. Results from studies comparing the use 
of iterative reconstruction techniques that can greatly lower 
the required medical radiation dose and newer model-based 
techniques and the issues in validating these dose reduction 
techniques were discussed.19 Currently, the dose required for 
lung screening is lower than that of CAC screening, and the 
challenge remains on developing a comprehensive approach 
to optimizing integration into a single protocol. This integra-
tion of lung cancer and atherosclerotic disease imaging has the 
potential for significant public health benefit if these analyses 
can be performed jointly with acceptable radiation exposure 
and reliable results.
A new opportunity to maximize clinical information 
from LDCT emerges with the evaluation of breast density 
as presented by Dr. Laurie Margolies. As the breasts are rou-
tinely included in the field of view in the course of a LDCT, 
the opportunity exists to analyze that information without 
incurring any additional medical radiation, imaging time or 
cost. As more women are screened for lung cancer, there is an 
opportunity to understand the potential complementary con-
tribution of this imaging study compared with mammography 
and to integrate this information into a comprehensive pro-
gram for breast health. A preliminary study was discussed that 
highlighted the importance of measuring breast density and 
demonstrated the correlation between scoring using LDCT 
compared with mammography.20 It showed highly favor-
able results and in addition demonstrated the potential for 
automated computer-assisted methods. Further research on 
CT-derived imaging information, such as with breast density 
assessment, is an important opportunity.
Dr. Tom Baer from Stanford University reviewed the 
status of quantitative imaging methods in areas other than 
with CT lung imaging. This presentation included imaging 
based on dynamic structure measurements, i.e., measure-
ments involving extracting key features derived from high-
resolution two-dimensional and three-dimensional images 
taken at multiple time points. He highlighted examples from 
the fields of cancer, neuroscience, and in vitro fertilization. 
These applications of quantitative dynamic imaging face simi-
lar challenges to those encountered with applying quantitative 
analysis for lung cancer screening management: generation 
of very large data sets, the need for development of feature 
extraction software, and ensuring the reproducibility of quan-
titative imaging data across different platforms and at differ-
ent time points. Solving these problems requires the assembly 
of highly skilled, multidisciplinary teams working collabora-
tively employing many of the development strategies being 
discussed for lung cancer screening research.
OTHER APPLICATIONS OF QUANTITATIVE 
IMAGING IN LUNG CANCER MANAGEMENT
The evolution of lung cancer surgery has been remark-
able. Dr. Nasser Altorki outlined the progress from extensive 
resection of an entire side of the lungs for more advanced 
symptom-detected lung cancer to the more tailored, endo-
scopic-mediated limited resection frequently done for the 
smaller, earlier stage, screen-detected lung cancer.21,22 As a 
result of this transition, there has been a significant reduc-
tion in surgical complications, which includes parameters, 
such as lower rates of atrial arrhythmias, lower reintubation 
rates, reduced need for blood transfusion, shorter duration of 
chest tube drainage, and decreased length of hospital stay. The 
smaller primary lung cancers found with screening may allow 
even more limited surgical procedures to be employed and 
early pilot experience with these approaches, and alternatives 
to surgery, including limited radiation therapy, are associated 
with even fewer complication rates. These developments are 
critical to improve the benefits/harms considerations with 
lung cancer screening as the field moves forward.
Just as the size and disease extent change the surgical 
approaches to manage screen-detected lung cancers, there 
are comparable opportunities to reengineer the approach to 
drug management in this setting. Dr. Natasha Leighl outlined 
options with preoperative or postoperative chemotherapy and 
preoperative window studies. These approaches would also 
involve in vitro drug selection based on molecularly directed 
companion diagnostics that are currently used in selecting the 
appropriate targeted therapy in advanced stage lung cancer. 
This is especially attractive for using molecular profiling to 
align the appropriate drug with the actual tumor resected from 
an early stage screen-detected cancer patient. Molecular tools 
can also be used to analyze tumor tissue to determine risk 
profiles beyond the usual clinical features and suggest who 
may benefit from exposure to specifically targeted adjuvant 
therapies as is often done with the management of early stage 
breast cancer. Dr. Leighl discussed the experience to date with 
neoadjuvant window trials, which provide an opportunity to 
assess how a patient is responding to a short course of drug 
administration. In this study design in consenting patients, 
an experimental drug is given for several weeks before sur-
gery.23 Images and tumor tissue are compared from before 
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and after the period of drug administration to understand what 
mechanistic impact the new drug is having on the cancer. This 
approach is particularly informative because the response to 
the drug can be matched to the actual status of the tumor’s 
cellular machinery. This gives the researcher much more 
granular information about the utility of a drug in this clinical 
setting, and this approach could inform the selection of drugs 
for complementary therapy of early lung cancer, such as with 
screen detected lung cancer or with adjuvant or chemopreven-
tive drug approaches.
COST IMPLICATIONS OF QUANTITATIVE 
IMAGING
In considering the implementation of a new clinical 
service, a fundamental issue is the cost of delivery. Bruce 
Pyenson, a principal actuarial at Milliman has been working on 
this question and reviewed the status of his current findings.24 
In summary, an actuarial analysis of actual cost of screen-
ing services based on current relevant Current Procedural 
Terminology (CPT) codes, shows that LDCT screening done 
in a fashion consistent with an International Early Lung Cancer 
Action Program or National Comprehensive Cancer Network 
protocol will result in relatively modest cost to Medicare of 
~$1 per member, per month in 2014 dollars versus ~$750 per 
member, per month for the full average cost of Part A and Part 
B. With that cost structure, the additional expense of imple-
menting lung cancer screening—if the rate of uptake of this 
service by the public is similar to the participation rate with 
colon cancer screening—will be about $700 million for the 
first year of national implementation of LDCT screening (with 
the total Part A and Part B expenditures ~$500 billion).
The screening costs do not vary much with nodule size 
follow-up thresholds. The anticipated cost-benefit would be in 
the range of $25,000 per life-year saved (2014 dollars), which 
compares very favorably with mammography and cervical 
cancer screening, and is similar to colorectal screening. From 
a financial analysis, LDCT screening represents a comparable 
investment with other validated organ-specific cancer screen-
ing activities but because lung cancer is currently so much 
more lethal than these other cancers, more public health ben-
efit will be potentially realized.25
OTHER HEALTH POLICY ASPECTS OF 
IMPLEMENTING LUNG CANCER SCREENING
The Patient Protection and Affordable Care Act provided 
funding not only for evidence-supported cancer screening 
services but also to start a new national network of patient-
centric comparative effectiveness research with cancer screen-
ing included as a key interest.26 This funding was intended to 
catalyze the evolution of important new clinical management 
approaches that greatly improve patient outcomes. Dr. Joseph 
Selby is the director of this new national effort, which is called 
the Patient Centered Outcomes Research Institute (PCORI). 
Dr. Selby came to the workshop to explore the intersection 
between patient-centric outcomes research and this new LDCT 
approach to find and cure early lung cancer. The mission of 
PCORI is to help people make informed health care decisions 
and improve health care delivery and outcomes, by producing 
and promoting high integrity, evidence-based information 
derived from research guided by patients, caregivers, and the 
broader health care community. The strategy of PCORI is to 
frame important research questions as a comparison between 
two or more options—for screening, diagnosis, or treatment. 
The trials will consider the range of clinical outcomes relevant 
to patients conducted in real world populations and real world 
settings.
An important goal is to evaluate differences in effec-
tiveness and preferences across patient subgroups, which fre-
quently will require a randomized trial design. PCORI intends 
to focus on important clinical questions but attempts to be sen-
sitive to variable outcomes as a function of clinical or cultural 
issues. As a result, PCORI has a greater emphasis on under-
standing personal risk and personal benefit, so individuals 
will be empowered to make better personal health decisions 
based on solid evidence. Over time, a number of clinical trial 
methodologies will be used to ask relevant questions but this 
approach will also use pragmatic trial designs where clinical 
information available through electronic medical records pro-
vides the data to examine the actual study question. Examples 
of this evolving approach were discussed, especially in regard 
to the “rapid learning” approaches endorsed by the National 
Academy of Sciences.27
Faced with this challenge of providing high quality, eco-
nomical and accessible community-based LDCT screening, 
Laurie Fenton Ambrose, President of the LCA, outlined how 
this organization is working toward a national solution. Along 
with a number of institutions that provide LDCT screening 
services, LCA has assembled a consortium called the National 
Framework for Excellence in Lung Cancer Screening. The 
central tenet is that all screening institutions will incorporate 
evidence-derived national best practices into the components 
of their screening process.28 These “Framework” institutions 
will track and make public their clinical outcomes, and they 
will continue to integrate improved approaches, so that the 
screening process continues to improve dynamically. Another 
crucial tenet of the “Framework” is recognition of the basic 
rights of an individual participating in lung cancer screen-
ing to have a clear and objective presentation of the poten-
tial harms and benefits of LDCT screening. To date over 180 
institutions across the United States have joined the consor-
tium and adopted its principles. The LCA is committed to 
ensuring that this mechanism is a conduit back to sites with 
regard to evolving information about improved screening 
approaches.
ACTION ITEMS RELATIVE TO HEALTH POLICY
Despite remarkable progress with the national imple-
mentation of lung cancer screening that is currently proceed-
ing, three health policy priorities emerged as important action 
items. The first was a proposal to send a letter to Centers for 
Medicare and Medicaid Services asking for full reimburse-
ment coverage of LDCT screening on a national level to 
ensure equitable access for this new and important cancer 
screening service. The next was to support the Department of 
Defense and its Healthy Base Initiative.29 The final recommen-
dation was to explore commissioning a study by the Institute 
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of Medicine of the National Academy of Sciences on imaging 
research as it relates to lung and heart diseases.
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